RONALD MOOMAW: Open Payments
NPI 1760504823 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,419 in 72 payments from 12 companies in 2025. Trend: 2023 $1,492 · 2024 $1,200 · 2025 $1,419
Food & beverage: $1,419
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $253 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $233 |
| Axsome Therapeutics, Inc. | 10 | $171 |
| Otsuka America Pharmaceutical, Inc. | 8 | $158 |
| Lundbeck LLC | 12 | $149 |
| Janssen Pharmaceuticals, Inc | 6 | $117 |
| E.R. Squibb & Sons, L.L.C. | 1 | $110 |
| Corium, LLC | 5 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Noven Therapeutics, LLC | 2 | $39 |
Products named: REXULTI, VRAYLAR, CAPLYTA, Auvelity, SPRAVATO, COBENFY, Azstarys, Sunosi.
Industry payments across TX — which companies pay providers there.
